Pluri Inc. has entered into a definitive agreement with ZEO ScientifiX, Inc. to license its regenerative medicine product portfolio for the United States. Under the terms of the agreement, ZEO will acquire a 41% equity stake in Pluri immediately following the closing of the transaction. Additionally, Pluri will receive warrants to purchase up to 7.5% of ZEO's issued share capital at specific exercise prices, as well as an additional 5% of ZEO's shares if the company's common stock reaches a volume-weighted average price of $5.50 per share over a ten-day period.
The partnership grants Pluri the right to designate four of seven board members at ZEO, contingent upon Pluri maintaining at least 25% ownership and avoiding a change of control. The agreement includes detailed protective provisions for the Series D Preferred Stock issued to Pluri, including rights to approve major corporate actions and a majority vote requirement for board removals.
In related financing news, Pluri entered into separate Securities Purchase Agreements with two undisclosed investment firms on October 27, 2026. The agreements provide for the issuance of 454,546 common shares per investor at a price of $1.10 per share, alongside warrants to purchase an equal number of shares at an exercise price of $1.30. The total subscription amount is $1,000,000, with an option for investors to pay in Israeli Shekels at an exchange rate of 3.0780 NIS per USD. The company expects these transactions to close on or before October 30, 2026.
